Unique ADP-ribosylating and vacuolating properties of Mycoplasma pneumoniae CARDS toxin trigger airway inflammation and disease progression
肺炎支原体卡毒素独特的 ADP-核糖基化和空泡特性触发气道炎症和疾病进展
基本信息
- 批准号:9882954
- 负责人:
- 金额:$ 45.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-01 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:ADP Ribose TransferasesADP ribosylationAcuteAdultAffectAirway DiseaseAllergic inflammationAmino Acyl Transfer RNAAnnexinsAsthmaBacterial PneumoniaBindingCarbonCell DegranulationCell LineCellsCharacteristicsChildChronicChronic Obstructive Airway DiseaseCommunitiesCommunity Acquired Respiratory Distress Syndrome ToxinComplexCytopathologyCytosolDiseaseDisease ProgressionDoseElongation FactorExhibitsFunctional disorderGlycine HydroxymethyltransferaseHistopathologyHumanIgEImmune responseInfectionInflammasomeInflammationInflammatoryInflammatory ResponseInjuryInterleukin-1 betaIntoxicationKnock-outKnockout MiceLeadLecithinLengthLower respiratory tract structureLungLung InflammationLung diseasesLymphocyteMediatingMembraneMembrane LipidsMetabolismMetaplasiaModalityMolecularMouse Cell LineMucous body substanceMusMycoplasma pneumonia infectionMycoplasma pneumoniaeN-terminalNatural ImmunityOrgan Culture TechniquesOrganellesPapioPathogenesisPathologicPathologyPathway interactionsPeripheral Blood Mononuclear CellPersonal SatisfactionPhenotypePhospholipidsPhysiologicalPlayPneumoniaPrimatesProcessPropertyProteinsPulmonary PathologyPulmonary Surfactant-Associated Protein ARespiration DisordersRibosomesRodentRoleSeveritiesShapesSphingomyelinsStructure of parenchyma of lungTestingTherapeuticTherapeutic InterventionTissuesToxinUnited StatesVacuoleWild Type Mouseadaptive immunityairway hyperresponsivenessairway inflammationairway remodelingbacterial communitybasecytokineeosinophileosinophilic inflammationimprovedin vivoinjured airwaymacrophagemast cellmicrobialmutantnovelpathogenprotein 50 kDaprototypepublic health relevancereceptorreceptor bindingrespiratoryrespiratory distress syndromeresponsetissue injury
项目摘要
Abstract
Mycoplasma pneumoniae is the leading cause of bacterial pneumonia in children hospitalized with
community acquired pneumonia (CAP) and the second most common cause of bacterial CAP in adults in the
United States. Persistent and recurring M. pneumoniae infection leads to severe respiratory disorders,
including asthma and COPD, and a range of extrapulmonary pathologies. Until recently, it was unknown how
a respiratory pathogen, like M. pneumoniae, induces cytopathology and exaggerated inflammatory
responses that cause airway injury, dysfunction and remodeling. We identified a novel M. pneumoniae ADP-
ribosylating and vacuolating toxin designated Community Acquired Respiratory Distress Syndrome (CARDS)
toxin. CARDS toxin alone elicits the characteristic airway inflammation, lung histopathology, cellular
vacuolation, mucus metaplasia and pulmonary dysfunction in intoxicated rodents and primates that are
observed during infection with M. pneumoniae. The amino terminal domain of full length (FL) CARDS toxin
(i.e., N-CARDS) retains ADP-ribosyltransferase (ART) activity. N-CARDS selectively ADP-ribosylates NLRP3
of the NLRP3 inflammasome complex, resulting in inflammasome activation and subsequent release of IL-
1β, a potent pro-inflammatory cytokine. In preliminary results, we also show that CARDS toxin selectively
ADP-ribosylates serine hydroxymethyltransferase (SHMT2), which is involved in one carbon metabolism, and
EF1γ, which is involved in the transfer of aminoacyl-tRNAs to the ribosome. The unique carboxyl region of FL
CARDS toxin (i.e., C-CARDS) selectively binds to receptors surfactant protein-A (SP-A), annexin A2 (AnxA2)
and phospholipids, phosphatidylcholine (PC) and sphingomyelin (SM). Internalization of FL CARDS toxin
follows receptor-mediated binding, with subsequent ADP-ribosylation of host target proteins, vacuolation,
hyperinflammation and cell/tissue histopathology and injury. Interestingly, C-CARDS alone causes both
vacuole formation in human cells and eosinophilic inflammation in naïve mice, leading to an asthma-like
phenotype. In this proposal, we intend to identify how ART and vacuolating properties of CARDS toxin trigger
pro-inflammatory and pathologic responses in human WT, silenced or knockout cells and in WT and
knockout mice. Based on our preliminary results, we hypothesize that both ADP-ribosylating and vacuolating
activities contribute to the overall ability of CARDS toxin to initiate and sustain disease pathogenesis. We
plan to test this hypothesis by – a) studying how CARDS toxin ART activities initiate inflammatory pathways
and cytopathology, b) elucidating the role of receptor binding in CARDS toxin-mediated inflammation, c)
characterizing how vacuolating activity promotes airway inflammation and injury, and d) analyzing the in vivo
involvement of select ART and receptor targets in triggering CARDS toxin-mediated airway inflammation and
lung pathology. Understanding the mechanisms by which ART and vacuolating activities of CARDS toxin
regulate host response should lead to therapeutic interventions and improved societal well-being.
摘要
肺炎支原体是住院儿童细菌性肺炎的主要原因
社区获得性肺炎(CAP)和成人细菌性CAP的第二大常见原因
美国。持续和反复感染肺炎支原体会导致严重的呼吸系统疾病,
包括哮喘和慢性阻塞性肺病,以及一系列肺外病理。直到最近,人们还不知道是如何
呼吸道病原体,如肺炎支原体,会引起细胞病理学和夸大炎症。
导致呼吸道损伤、功能障碍和重塑的反应。我们鉴定出一种新的肺炎支原体ADP-
核糖化和空泡化毒素指定社区获得性呼吸窘迫综合征(CADS)
毒素。卡氏毒素单独引起典型的呼吸道炎症、肺组织病理学、细胞学
中毒的啮齿动物和灵长类动物的空泡化、粘液化生和肺功能障碍
在肺炎支原体感染期间观察。全长(FL)卡片毒素的氨基端结构域
(即N-卡片)保持ADP-核糖基转移酶(ART)活性。N-卡片选择性ADP-核糖化NLRP3
NLRP3炎症体复合体,导致炎症体激活并随后释放IL-2
1β,一种强有力的促炎细胞因子。在初步结果中,我们还显示CARDS毒素具有选择性。
ADP-核糖酸丝氨酸羟甲基转移酶(SHMT2),参与一种碳代谢,以及
Ef1γ,参与氨酰-tRNA向核糖体的转移。FL独特的羧基区
CARDS毒素(即C-CADS)选择性地与受体表面活性蛋白A(SP-A)、膜联蛋白A2(AnxA2)结合
磷脂、磷脂酰胆碱(PC)和鞘磷脂(SM)。FL卡片毒素的内化
遵循受体介导的结合,随后宿主靶蛋白的ADP核糖化,空泡化,
高度炎症、细胞/组织病理学和损伤。有趣的是,C卡本身就导致了这两种情况
人类细胞中空泡的形成和幼稚小鼠的嗜酸性炎症,导致哮喘样
表型。在这项建议中,我们打算确定ART和CARDS毒素的空泡化特性如何触发
人WT、沉默或敲除细胞以及WT和WT中的促炎和病理反应
基因敲除老鼠。根据我们的初步结果,我们假设ADP-核糖化和空泡化
这些活动有助于CARDS毒素启动和维持疾病发病机制的整体能力。我们
计划通过以下方式验证这一假设:a)研究卡片毒素ART活动如何引发炎症途径
和细胞病理学,b)阐明受体结合在CARDS毒素介导的炎症中的作用,c)
表征空泡化活动如何促进呼吸道炎症和损伤,以及d)分析体内
部分ART和受体靶点参与触发CARS毒素介导的呼吸道炎症和
肺部病理。了解CARDS毒素的ART和空泡化活性的机制
调节宿主的反应应该导致治疗干预和改善社会福祉。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thirumalai Rengasamy Kannan其他文献
Thirumalai Rengasamy Kannan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thirumalai Rengasamy Kannan', 18)}}的其他基金
Unique ADP-ribosylating and vacuolating properties of Mycoplasma pneumoniae CARDS toxin trigger airway inflammation and disease progression
肺炎支原体卡毒素独特的 ADP-核糖基化和空泡特性触发气道炎症和疾病进展
- 批准号:
10338093 - 财政年份:2019
- 资助金额:
$ 45.61万 - 项目类别:
Unique ADP-ribosylating and vacuolating properties of Mycoplasma pneumoniae CARDS toxin trigger airway inflammation and disease progression
肺炎支原体卡毒素独特的 ADP-核糖基化和空泡特性触发气道炎症和疾病进展
- 批准号:
10578740 - 财政年份:2019
- 资助金额:
$ 45.61万 - 项目类别:
Unique ADP-ribosylating and vacuolating properties of Mycoplasma pneumoniae CARDS toxin trigger airway inflammation and disease progression
肺炎支原体卡毒素独特的 ADP-核糖基化和空泡特性触发气道炎症和疾病进展
- 批准号:
9762435 - 财政年份:2019
- 资助金额:
$ 45.61万 - 项目类别:
相似海外基金
Control of genomic integrity and virulence of Aspergillus fumigatus by ADP-ribosylation.
通过 ADP-核糖基化控制烟曲霉的基因组完整性和毒力。
- 批准号:
MR/X007472/1 - 财政年份:2023
- 资助金额:
$ 45.61万 - 项目类别:
Fellowship
Understanding the impact of DNA ADP-ribosylation on telomere function in cancer cells
了解 DNA ADP-核糖基化对癌细胞端粒功能的影响
- 批准号:
10751121 - 财政年份:2023
- 资助金额:
$ 45.61万 - 项目类别:
Composition and function of telomeric multi-protein complexes and their regulation by ADP-ribosylation
端粒多蛋白复合物的组成和功能及其ADP-核糖基化的调节
- 批准号:
2748032 - 财政年份:2022
- 资助金额:
$ 45.61万 - 项目类别:
Studentship
A Chemical Footprinting Approach towards Poly-ADP-Ribosylation-regulated Biomolecular Condensation
聚 ADP 核糖基化调节生物分子缩合的化学足迹方法
- 批准号:
10524783 - 财政年份:2022
- 资助金额:
$ 45.61万 - 项目类别:
Regulation of DNA repair by histone ADP-ribosylation
组蛋白 ADP 核糖基化调节 DNA 修复
- 批准号:
MR/W017350/1 - 财政年份:2022
- 资助金额:
$ 45.61万 - 项目类别:
Research Grant
Regulation and function of site-specific protein poly-ADP-ribosylation
位点特异性蛋白质聚 ADP 核糖基化的调控和功能
- 批准号:
10668492 - 财政年份:2022
- 资助金额:
$ 45.61万 - 项目类别:
ADP-ribosylation of DNA in Mycobacterium tuberculosis
结核分枝杆菌 DNA 的 ADP-核糖基化
- 批准号:
BB/W016613/1 - 财政年份:2022
- 资助金额:
$ 45.61万 - 项目类别:
Research Grant
A Chemical Footprinting Approach towards Poly-ADP-Ribosylation-regulated Biomolecular Condensation
聚 ADP 核糖基化调节生物分子缩合的化学足迹方法
- 批准号:
10610165 - 财政年份:2022
- 资助金额:
$ 45.61万 - 项目类别:
Role of Transcription Factor ADP-ribosylation in Breast Cancer Biology
转录因子 ADP-核糖基化在乳腺癌生物学中的作用
- 批准号:
10593900 - 财政年份:2021
- 资助金额:
$ 45.61万 - 项目类别:
A Chemical Footprinting Approach towards Poly-ADP-Ribosylation-regulated Biomolecular Condensation
聚 ADP 核糖基化调节生物分子缩合的化学足迹方法
- 批准号:
10389853 - 财政年份:2021
- 资助金额:
$ 45.61万 - 项目类别:














{{item.name}}会员




